Medullary thyroid carcinoma is a relatively rare malignant neoplasm arising from the parafollicular cells, or C cells, of the thyroid, which are responsible for the secretion of calcitonin. Unlike differentiated thyroid carcinomas, this neoplasm does not originate from follicular cells and does not retain the ability to take up iodine, therefore displaying clearly distinct biological, clinical, and therapeutic characteristics. Medullary carcinoma accounts for a minority of thyroid cancers but is responsible for a substantial proportion of thyroid cancer-specific mortality because of its often more aggressive behavior and greater tendency toward early dissemination. It may occur in a sporadic or hereditary form, the latter being associated with germline mutations of the RET proto-oncogene and occurring within the spectrum of multiple endocrine neoplasia. Diagnosis may be incidental during the evaluation of a thyroid nodule, but the disease is not uncommonly identified at an advanced stage, when lymph node or distant metastases are already present.
The natural history of medullary thyroid carcinoma is characterized by variable growth, with relatively indolent forms and others showing rapid progression. The neoplasm tends to spread early to the cervical and mediastinal lymph nodes, while hematogenous dissemination may involve the liver, lungs, and skeleton. Unlike differentiated carcinomas, symptoms may also be influenced by the secretory activity of the tumor, with systemic manifestations related to the production of calcitonin and other biologically active peptides. Diagnosis is based on a structured pathway integrating neck ultrasonography, cytological fine-needle aspiration with measurement of calcitonin in the needle washout, biochemical assessment, and imaging for staging. Early recognition is crucial because surgery represents the only potentially curative option.
The treatment of medullary thyroid carcinoma is primarily surgical and requires careful planning according to the extent of disease and its possible hereditary nature. Management should ideally be undertaken in highly specialized centers, with the involvement of endocrinologists, endocrine surgeons, oncologists, geneticists, and nuclear medicine specialists. Despite advances in molecular diagnosis and the development of targeted systemic therapies, prognosis remains closely dependent on the stage at diagnosis, making early identification strategies in high-risk individuals essential.
The epidemiology of medullary thyroid carcinoma differs markedly from that of other thyroid tumors because of its lower frequency and the importance of its genetic component. Globally, medullary carcinoma accounts for a small percentage of all thyroid neoplasms, with a relatively stable incidence over time and without the marked increase observed for differentiated carcinomas. The rarity of the disease makes large-scale epidemiological assessment difficult, but consolidated data indicate that it contributes disproportionately to thyroid cancer mortality, particularly among cases diagnosed at an advanced stage.
From a demographic perspective, sporadic medullary carcinoma occurs more frequently in adulthood, with a peak between the fifth and sixth decades of life, and shows a more balanced sex distribution than papillary carcinoma, although a slight female predominance has been reported in some series. In contrast, hereditary forms may arise much earlier, sometimes during childhood or adolescence, depending on the specific genetic mutation involved.
The main risk factor consists of germline mutations of the RET proto-oncogene, which are responsible for familial forms of medullary thyroid carcinoma. These mutations are associated with multiple endocrine neoplasia type 2 syndromes, including MEN 2A and MEN 2B, and with isolated familial medullary carcinoma. In these settings, the risk of developing the tumor is extremely high, and penetrance varies according to the specific mutation. Early identification of carriers enables effective preventive strategies, including prophylactic surgery.
Most sporadic cases instead harbor somatic RET mutations or alterations in other genes involved in cellular signaling pathways, leading to constitutive activation of C-cell proliferation. Although these alterations are not environmental risk factors, they influence the biological behavior of the tumor and have prognostic and therapeutic relevance. Unlike other thyroid tumors, there is no robust evidence linking medullary carcinoma to exposure to ionizing radiation or to nutritional factors such as iodine status.
Clinical conditions associated with the hormonal secretion of the tumor may influence its presentation but do not represent risk factors for the development of the neoplasm. In some families, medullary carcinoma occurs together with other endocrine manifestations, such as pheochromocytoma and hyperparathyroidism, producing complex syndromic conditions that require an integrated approach. Overall, the risk profile of medullary thyroid carcinoma is dominated by its genetic component, making genetic counseling and family screening central elements of management.
Taken together, these features define an epidemiological profile in which medullary thyroid carcinoma emerges as a rare but clinically relevant neoplasm, for which the identification of individuals at high risk is essential to improve long-term outcomes.
There are no population-based screening programs for medullary thyroid carcinoma. Its low incidence in the general population and the absence of simple, noninvasive tests with adequate specificity make indiscriminate screening unjustified. However, unlike other thyroid neoplasms, there are clearly defined settings in which screening and surveillance play a decisive role.
In individuals with germline RET mutations, genetic screening is the fundamental tool for early identification of the disease. In asymptomatic carriers, biochemical surveillance through serum calcitonin measurement and clinical monitoring allows a prophylactic thyroidectomy to be scheduled at the appropriate age, often before clinically apparent disease develops. The timing of surgery is adjusted according to the type of mutation and the associated risk, in accordance with internationally shared protocols.
In patients with sporadic medullary carcinoma, the initial evaluation of a thyroid nodule may include calcitonin measurement, particularly in the presence of suspicious ultrasonographic features or inconclusive cytology. Although the routine use of calcitonin as a screening test in patients with thyroid nodules remains debated, its targeted use may facilitate an earlier diagnosis than cytological assessment alone.
After surgical treatment, post-treatment surveillance is a central component of clinical management. Follow-up is based on serial monitoring of calcitonin and carcinoembryonic antigen, which allows the early detection of residual or recurrent disease. Neck ultrasonography and second-line imaging are used when markers are elevated or rising, with the aim of localizing any sites of disease.
In patients with hereditary syndromes, surveillance also extends to the detection of other associated endocrine neoplasms, particularly pheochromocytoma, which must be excluded before any thyroid surgical procedure. This integrated approach reduces the risk of complications and enables comprehensive management of both the patient and at-risk relatives.
Overall, screening for medullary thyroid carcinoma is not indicated in the general population, but selective surveillance of individuals at high genetic risk and structured follow-up of treated patients are essential strategies. The effectiveness of these approaches depends on the early identification of mutation carriers, the integration of genetic, biochemical, and instrumental assessment, and management within highly specialized multidisciplinary settings.
The biology of medullary thyroid carcinoma originates from the parafollicular C cells, neuroendocrine elements derived from the neural crest and responsible for calcitonin secretion. Unlike differentiated thyroid carcinomas, this neoplasm does not arise from the follicular epithelium and does not participate in thyroid hormone synthesis. Under physiological conditions, C cells maintain low proliferative activity and regulated secretion. Neoplastic transformation is associated with the aberrant activation of growth programs that preserve the neuroendocrine phenotype but lead to loss of normal proliferative control.
A central role in pathogenesis is played by the constitutive activation of the RET receptor tyrosine kinase. In medullary thyroid carcinoma, this activation may result from germline or somatic mutations that produce autonomous signaling independently of ligand binding. Hereditary forms, including those associated with multiple endocrine neoplasia type 2, are characterized by germline RET mutations that induce early transformation of C cells, often preceded by diffuse hyperplasia. In sporadic forms, somatic mutations of RET or, in a proportion of cases, RAS, support clonal proliferation and tumor progression.
From a genetic perspective, medullary carcinoma harbors a relatively limited number of driver events, with RET acting as the main biological determinant. RET mutations located in the extracellular domain or tyrosine kinase domain produce differences in the strength of proliferative signaling and in clinical aggressiveness. RAS mutations, which are more frequent in RET-negative sporadic forms, activate overlapping mitogenic pathways, particularly the MAPK cascade, despite the absence of direct RET alterations. Overall genomic instability is generally lower than in less differentiated thyroid neoplasms, although it may increase during advanced stages.
Epigenetic alterations contribute to modulation of the tumor phenotype. Changes in DNA methylation and histone regulation influence the expression of genes involved in hormonal secretion, cell migration, and the stress response. Specific microRNAs are also dysregulated, with effects on cell-cycle control and invasiveness that complement the action of driver mutations.
The tumor microenvironment is characterized by a stroma rich in amyloid deposits derived from the aggregation of calcitonin-related peptides secreted by neoplastic cells. This extracellular material is a distinctive feature of medullary carcinoma and contributes to its histological identification. Interactions among tumor cells, fibroblasts, and the vascular compartment promote angiogenesis and extracellular matrix remodeling, facilitating local invasion and lymphatic and hematogenous dissemination.
From an immunological perspective, medullary thyroid carcinoma generally displays a microenvironment with a limited effective lymphocytic infiltrate. The expression of immunomodulatory molecules and the secretion of soluble mediators contribute to a relatively tolerogenic environment. The ability to produce hormonal and neuroendocrine peptides also gives the tumor a distinctive biological profile with potential systemic effects.
On the basis of biological and genetic characteristics, the following forms are recognized:
From a histological perspective, medullary carcinoma is characterized by nests, trabeculae, or sheets of polygonal or spindle-shaped cells, with granular cytoplasm and relatively uniform nuclei. Stromal amyloid deposition is a distinctive finding. Histological variants may display different growth patterns and degrees of atypia, with variable correlation with clinical aggressiveness.
Immunohistochemistry is essential for diagnosis. Tumor cells express calcitonin, CEA, and neuroendocrine markers such as chromogranin A and synaptophysin, while they are negative for thyroglobulin. The proliferative index assessed using Ki-67 provides information on mitotic activity and aggressive potential. Assessment of vascular and perineural invasion contributes to risk stratification.
Overall, medullary thyroid carcinoma is a neuroendocrine neoplasm strongly dependent on specific molecular alterations, particularly RET abnormalities, and has a biological phenotype distinct from that of other forms of thyroid carcinoma. This uniqueness accounts for its different clinical behavior and specific diagnostic and therapeutic implications.
The clinical manifestations of medullary thyroid carcinoma are heterogeneous and depend on local tumor growth, lymph node or distant spread, and the secretion of hormonal peptides. In a substantial proportion of patients, onset is insidious and the tumor is identified as a thyroid nodule during ultrasonographic investigations performed for other reasons. Growth may be slow during the initial stages, but the overall clinical behavior is more aggressive than that of differentiated thyroid carcinomas.
The most common finding is a hard thyroid nodule that is often poorly demarcated and may be fixed to the deep planes. Thyroid function is generally preserved, and patients remain euthyroid. As the lesion increases in size, it may cause cervical compressive symptoms, including a sensation of pressure or a foreign body, dysphagia, and, in more advanced cases, dyspnea caused by tracheal compression.
Clinical presentation varies according to the extent of disease:
A distinctive feature of medullary carcinoma is the possibility of manifestations related to the secretion of calcitonin and other bioactive peptides. Some patients may develop chronic watery diarrhea, abdominal cramps, and dehydration secondary to the systemic secretory effects of the tumor. These symptoms may precede diagnosis or arise during advanced stages, contributing to a significant deterioration in quality of life.
Regional lymph node spread is common and may represent the first clinical manifestation. Cervical lymphadenopathy may be bulky and involve multiple nodes. Distant dissemination most commonly affects the liver, lungs, and bones, causing symptoms such as bone pain, pathological fractures, dyspnea, or hepatomegaly. In advanced forms, weight loss, marked fatigue, and deterioration in general condition may occur.
In hereditary forms, medullary carcinoma may be associated with other endocrine manifestations, such as pheochromocytomas or hyperparathyroidism, which influence the overall clinical presentation. In these settings, the disease may be diagnosed early through genetic surveillance programs, often before local symptoms develop.
Physical examination may reveal hard thyroid nodules, reduced movement of the gland during swallowing, and cervical lymphadenopathy. The presence of dysphonia, compressive symptoms, and systemic signs should prompt an in-depth evaluation. Overall, medullary thyroid carcinoma has a variable clinical presentation in which the combination of local findings and systemic manifestations reflects its distinctive neuroendocrine biology.
The diagnostic assessment of medullary thyroid carcinoma begins with clinical, biochemical, or instrumental suspicion and proceeds through a sequence of investigations aimed first at confirming the neuroendocrine nature of the neoplasm, then at excluding alternative diagnoses, and finally at defining the extent of disease without yet introducing formal staging. Suspicion may arise in the presence of a thyroid nodule, lateral cervical lymphadenopathy, local compressive symptoms, or systemic manifestations related to hormonal secretion, such as chronic diarrhea or flushing. In a substantial proportion of cases, the diagnosis is made incidentally during the evaluation of an apparently asymptomatic thyroid nodule.
A distinctive feature of medullary carcinoma is the central role of biochemical tests. Measurement of serum calcitonin is the most sensitive investigation for diagnostic suspicion and should be performed in all patients with a suspicious thyroid nodule or indeterminate cytology. Persistently elevated or clearly abnormal values are highly suggestive of medullary carcinoma. Measurement of CEA provides complementary information and is useful both during diagnosis and as a prognostic baseline. In selected cases, stimulation tests may be used to clarify borderline findings.
Neck ultrasonography is the first-line imaging examination and allows detailed assessment of the thyroid and cervical lymph node compartments. Suspicious nodules may display variable and less typical ultrasonographic features than papillary carcinoma, making systematic evaluation of the central and lateral cervical lymph nodes essential. Identification of suspicious lymphadenopathy supports the early adoption of a more extensive diagnostic and therapeutic approach.
Ultrasound-guided thyroid fine-needle aspiration (FNA) is a crucial step in the diagnostic pathway. However, in medullary carcinoma, cytology may be less specific than in other histological types, with findings that may overlap with other neoplasms or indeterminate lesions. In this setting, measurement of calcitonin in the fine-needle aspiration washout fluid significantly increases diagnostic accuracy and strengthens the suspicion of a medullary origin.
Definitive diagnosis is established through histological examination, which demonstrates a proliferation of neuroendocrine cells arranged in nests, trabeculae, or solid structures within a stroma that is often rich in amyloid deposits. Immunohistochemistry plays an essential role by demonstrating the expression of calcitonin, CEA, and other neuroendocrine markers, thereby allowing medullary carcinoma to be distinguished from differentiated thyroid carcinomas, anaplastic neoplasms, and metastases from other sites.
According to the principal international guidelines, a minimum set of clinical, biochemical, and pathological elements is required before a diagnosis of medullary thyroid carcinoma can be considered established. Although these do not constitute formal “diagnostic criteria,” they represent essential requirements for a reliable diagnosis:
Elements required to establish a diagnosis of medullary thyroid carcinoma
Once the diagnosis has been established, the differential diagnosis must include differentiated thyroid carcinomas, anaplastic carcinoma, metastatic neuroendocrine neoplasms, and other rare thyroid lesions. Integration of clinical, biochemical, cytological, and immunohistochemical findings allows a clear distinction in most cases.
After completion of the diagnostic assessment, investigations focus on the evaluation of disease extent. Neck ultrasonography remains central for the assessment of regional lymph nodes. Contrast-enhanced computed tomography of the neck, chest, and upper abdomen is indicated in the presence of elevated calcitonin or clinical suspicion of advanced disease to identify extensive lymph node metastases or distant localizations, particularly in the liver and lungs. Magnetic resonance imaging and PET using appropriate tracers may be employed in selected settings to complete the evaluation.
In summary, the diagnostic pathway for medullary thyroid carcinoma follows a practical sequence: clinical or biochemical suspicion; measurement of calcitonin and CEA; neck ultrasonography; thyroid fine-needle aspiration with biochemical integration; histological confirmation; and subsequent assessment of disease extent using second-line imaging.
Staging of medullary thyroid carcinoma provides a standardized description of the anatomical extent of disease, supports treatment planning, and offers prognostic information. The international reference system is the eighth edition of the AJCC/UICC TNM classification, which for this histological type follows a logic more similar to that used for other solid neoplasms, without the age-dependent modification applied to differentiated thyroid carcinomas.
Clinical cTNM staging integrates data from neck ultrasonography, cross-sectional imaging, and biochemical assessment, while pathological pTNM staging, when available, allows a more accurate definition through direct examination of the surgical specimen and removed lymph nodes.
Conceptually, the main stage groups of medullary thyroid carcinoma according to the eighth edition of the AJCC/UICC classification can be summarized as follows:
Main stage groups in medullary thyroid carcinoma, AJCC/UICC eighth edition
From a prognostic perspective, medullary thyroid carcinoma has a more aggressive course than differentiated thyroid carcinomas, with overall survival closely related to the stage at diagnosis. Localized forms have a relatively favorable prognosis, while extensive lymph node metastases or distant metastases are associated with a significant reduction in survival.
Biochemical markers play a fundamental prognostic role. Baseline calcitonin and CEA levels, together with their doubling times during follow-up, are powerful predictors of progression and survival and may be more informative than anatomical staging alone when defining individual risk.
Additional prognostic factors include lymph node burden, extrathyroidal extension, completeness of surgical resection, and, in familial cases, the genetic context associated with RET mutations. Integration of TNM staging with biochemical parameters allows a more accurate and dynamic prognostic assessment.
Overall, staging of medullary thyroid carcinoma is an integrated process combining the anatomical extent and biological behavior of the disease. Prognosis differs substantially between localized and advanced forms, making early diagnosis and accurate initial risk stratification crucial.
The treatment of medullary thyroid carcinoma is based predominantly on surgery, selectively integrated with locoregional and systemic therapies in advanced forms. Unlike differentiated thyroid carcinomas, this neoplasm arises from the parafollicular C cells and does not take up radioactive iodine, making radioiodine therapy ineffective. The therapeutic strategy is defined according to disease extent, the presence of lymph node or distant metastases, biochemical marker levels, genetic profile, and the patient’s clinical condition within an expert multidisciplinary assessment.
Surgery is the cornerstone of treatment with curative intent. The standard procedure is total thyroidectomy, which is also indicated for small tumors because of the high frequency of multifocality and the need for complete oncological control. Concurrent central compartment lymph node dissection is recommended even in the absence of clinical evidence of metastases, because lymph node involvement is common and may occur at an early stage. Management of the lateral neck compartments is instead guided by preoperative or intraoperative evidence of lymph node metastases.
In forms with advanced locoregional disease, surgery may require extensive procedures, including resection of infiltrated adjacent structures such as muscles, the trachea, or nerves, with the aim of achieving complete macroscopic resection. In these settings, balancing oncological radicality with functional preservation is crucial and depends largely on the expertise of the treating center. When complete resection cannot be achieved, surgery may still have a debulking role to reduce tumor burden and prevent local complications.
External beam radiotherapy does not have a standard role in primary treatment but may be considered in selected situations, such as unresectable microscopic or macroscopic residual disease, inoperable local recurrence, or a high risk of local relapse. Its primary objective is locoregional control rather than an improvement in overall survival.
In metastatic or unresectable locally advanced disease, treatment becomes systemic. Traditional cytotoxic therapies have demonstrated limited efficacy, whereas the introduction of targeted therapies has substantially changed the therapeutic approach. Tyrosine kinase inhibitors acting on the principal pathways involved in the pathogenesis of medullary carcinoma, particularly in tumors with activating RET mutations, have demonstrated prolonged progression-free survival in patients with advanced and progressive disease. The decision to initiate systemic therapy is based on evidence of radiological progression, clinical symptoms, disease burden, and tumor growth rate.
Management of medullary carcinoma also includes control of the systemic manifestations associated with hormonal secretion. Diarrhea, flushing, and electrolyte disturbances may be clinically relevant in patients with a high tumor burden and require specific symptomatic treatments in addition to antineoplastic therapy. Nutritional and metabolic support plays a central role in advanced cases, helping maintain adequate treatment tolerance and preserve quality of life.
A distinctive aspect of treatment is the management of patients with germline RET mutations. In these individuals, medullary carcinoma may develop at an early age, and prophylactic surgery is a fundamental preventive strategy. Although this procedure belongs to the context of primary prevention rather than treatment of clinically manifest disease, appropriate planning has a decisive impact on prognosis and the natural history of the neoplasm.
Follow-up and post-treatment surveillance of medullary thyroid carcinoma are based primarily on biochemical monitoring integrated with targeted imaging. Unlike differentiated thyroid carcinomas, no functional iodine-related markers are available, and surveillance relies on the trend of specific tumor markers produced by C cells.
Calcitonin is the principal marker of disease. Following radical surgery, normalization or a marked reduction in serum levels indicates a complete response. Persistently elevated or progressively increasing values suggest residual or recurrent disease. The calcitonin doubling time is an important prognostic indicator, with rapid doubling associated with a more aggressive course.
Alongside calcitonin, CEA is used as a complementary marker. A discordant increase in CEA relative to calcitonin may indicate tumor dedifferentiation and greater biological aggressiveness, requiring careful clinical and instrumental reassessment.
Neck ultrasonography is the first-line examination for locoregional surveillance and is useful for identifying recurrence in the thyroid bed or cervical lymph node metastases. When clinical or biochemical suspicion is present, ultrasound-guided fine-needle aspiration allows cytological and biochemical confirmation through calcitonin measurement in the washout fluid.
When marker levels are elevated without clear ultrasonographic localization, or in the presence of advanced disease, follow-up is extended to second-line imaging examinations. Computed tomography and magnetic resonance imaging are used to assess the mediastinum, lungs, liver, and skeleton, which are common sites of metastasis. Functional techniques such as 18F-FDG PET may be employed in more aggressive cases or when markers are elevated and conventional imaging is negative.
In patients receiving systemic therapies, follow-up includes periodic assessment of radiological response and toxicity. Clinical monitoring should include evaluation of cardiovascular, gastrointestinal, and cutaneous adverse effects, which are frequently associated with tyrosine kinase inhibitors, with dose adjustments or temporary treatment interruptions when required.
An essential component of follow-up is genetic and family surveillance. In patients with hereditary disease, monitoring extends to relatives who carry the mutation and require dedicated follow-up or scheduled preventive interventions. Even in patients with apparently sporadic disease, genetic reassessment may be indicated when suggestive clinical features are present.
Follow-up is generally lifelong because of the possibility of late recurrence and the often indolent but persistent nature of the disease. In patients with a complete and stable biochemical response, control intervals may be progressively extended while maintaining regular marker surveillance. In cases of persistent or progressive disease, follow-up remains more frequent and is directed toward the timely detection of clinically significant progression.
In summary, post-treatment surveillance of medullary thyroid carcinoma is based on accurate and dynamic biochemical monitoring integrated with selective imaging and continuous clinical assessment. This approach allows early detection of disease recurrence, guides therapeutic decisions, and helps preserve long-term quality of life as far as possible.
Long-term quality-of-life considerations in medullary thyroid carcinoma are a fundamental component of comprehensive patient management because this relatively rare neoplasm has biological and clinical characteristics that may persistently affect physical and psychosocial well-being. Even in patients free from macroscopic disease, living with functional consequences, the need for prolonged surveillance, and possible systemic manifestations may substantially affect daily life.
A central element is the postoperative endocrine status. Total thyroidectomy, often combined with extensive lymph node dissection, results in permanent dependence on thyroid hormone replacement therapy with levothyroxine. Although thyroid-stimulating hormone suppression is not indicated in medullary carcinoma, hormonal balance must be carefully maintained to prevent symptoms such as fatigue, weight changes, mood disturbances, and reduced working capacity, which may impair long-term quality of life.
Voice and swallowing function are particularly important. Extensive surgical procedures in the cervical compartment increase the risk of persistent voice changes, vocal fatigue, and, in more complex cases, chronic dysphagia. Even mild disturbances may have a significant impact on communication, self-esteem, and social relationships, particularly in patients of working age.
In medullary carcinoma, systemic manifestations related to hormonal secretion may directly affect quality of life. Episodes of chronic diarrhea, flushing, and vasomotor disturbances related to the production of calcitonin or other bioactive substances may persist even during stable disease and limit personal independence and participation in social life.
The genetic dimension of the disease, especially in cases associated with germline RET mutations, introduces additional complexity. Awareness of a hereditary condition, the involvement of relatives, and the need for genetic and clinical surveillance of family members may create a substantial emotional burden, including anxiety, a sense of responsibility, and concern for the health of relatives.
The psychological and psychosocial dimension is strongly influenced by the chronic nature of follow-up. The possibility of biochemically persistent disease, even in the absence of radiological evidence, may generate prognostic uncertainty and heightened vigilance regarding symptoms. In patients with advanced or progressive disease, the emotional impact of systemic treatments and their toxicities further contributes to reduced overall well-being.
Overall, long-term quality of life in medullary thyroid carcinoma depends on the ability of the healthcare system to provide multidimensional care integrating oncological control with management of functional consequences, nutritional and psychological support, and appropriate genetic information. Quality of life is therefore an essential clinical outcome that should be considered alongside biological and radiological indicators when assessing the overall effectiveness of treatment.
The complications of medullary thyroid carcinoma arise from the interaction among disease biology, surgical extent, and systemic treatments, resulting in a potentially complex clinical condition that requires continuous monitoring and specialist management. Unlike differentiated thyroid carcinomas, the tendency toward persistent or progressive disease makes long-term surveillance particularly important.
Disease progression may present with cervical and mediastinal lymph node recurrence or distant metastases, particularly in the liver, bones, and lungs. These localizations may cause pain, functional impairment, metabolic abnormalities, and progressive deterioration of general condition. Persistent elevations in calcitonin and CEA are often associated with an increasing symptom burden.
The frequently required extensive thyroid surgery carries a significant risk of complications. Hypoparathyroidism, particularly after bilateral lymph node dissection, may become permanent and require chronic calcium and vitamin D supplementation, with a risk of symptomatic hypocalcemia. Laryngeal nerve injuries may cause dysphonia, dysphagia, and aspiration risk, with a marked impact on quality of life. Cervical hematomas, infections, and postoperative fibrosis may further complicate the course.
Systemic paraneoplastic manifestations are a distinctive feature of medullary carcinoma. Chronic secretory diarrhea, which may be severe, can lead to dehydration, electrolyte imbalances, and malnutrition. Flushing and vasomotor disturbances contribute to physical and social discomfort, particularly during active disease.
Targeted systemic treatments used in advanced or progressive forms are associated with specific toxicities. Tyrosine kinase inhibitors may cause arterial hypertension, gastrointestinal disturbances, fatigue, cutaneous abnormalities, cardiac dysfunction, and an increased risk of thromboembolic events. These complications require close clinical and laboratory monitoring and may necessitate dose reductions or temporary treatment interruption.
Repeated procedures for the treatment of local or lymph node recurrence increase the cumulative risk of surgical complications, cervical fibrosis, and nerve injury, making the patient’s clinical and surgical management progressively more complex.
More broadly, the chronic nature of the disease and the need for frequent monitoring may promote anxiety, emotional fatigue, and reduced perceived quality of life. In patients with advanced disease, the symptomatic and therapeutic burden requires an integrated approach that includes early symptom control and palliative support.
Effective management of complications is based on structured prevention, including surgery in highly experienced centers, accurate endocrine and metabolic monitoring, assessment of voice and nutritional function, surveillance of systemic treatment toxicities, and multidisciplinary integration of expertise. This approach reduces morbidity, preserves quality of life, and optimizes long-term care pathways.